Please visit our new website at www.export.gov!

Healthcare Resource Guide: Japan

JAPAN Statistics

Summary

Market Entry

Current Market Trends

Main Competitors

Current Demand

Registration Process

Barriers

Trade Events

FAQs

CS Contacts

Best Prospects

Market Size

Capital: Tokyo

Population: 126,702,133 (2016)

GDP*: $4.73 trillion (2016)

Currency: Yen (JPY/¥)

Language: Japanese

Summary

Japan‘s market for medical devices and materials continues to be among the world‘s largest. According to the latest official figures from the Ministry of Health, Labour and Welfare (MHLW) Annual Pharmaceutical Production Statistics, the Japanese market for medical devices and materials in 2015 was approximately $22.7 billion (down 1.4 percent from 2014 in yen terms). From 2010 to 2015, Japan's medical device market exhibited a compound annual growth rate (CAGR) of 3.5% in Yen terms. The market remains heavily dependent on imports, especially sophisticated medical devices. The demand for advanced medical technologies is expected to increase as Japan has a fast-aging demographic profile, with relatively prosperous seniors holding increasing expectations for improved quality of life in their later years. Business Monitor International estimated that Japan's medical device market will exhibit a CAGR of 4.1% from 2016 to 2021.

Policy Corner

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) continues to speed up the overall review time for pharmaceutical regulatory approval. Japan’s premium pricing system trial has allowed foreign pharmaceutical companies to bring their products to Japan more quickly but companies have expressed concern that pharmaceutical pricing faces downward pressure for innovative products. Strong financial pressure is constraining healthcare spending, in part due to the rapid aging of Japan's population. Biotechnology is an area that could offer more opportunities for U.S. exports, including biosimilar/FOPPs (follow-on protein products). Following the enactment of two regenerative medicine-related laws in late 2014, Japan also started attracting international attention to business opportunities related to stem cells.

Market Entry

A Japanese company that intends to market a U.S. medical device needs to receive a “license for manufacturing/marketing business” (seizo hanbai gyo kyoka). The company holding this license is called a “Marketing Authorization Holder (MAH)”. An MAH must be physically located in Japan. The MAH must obtain marketing approval (hanbai shonin) for each product. A U.S. manufacturer intending to manufacture medical devices in the United States and export them to Japan is required to be registered by the Pharmaceutical and Medical Device Agency (PMDA) as a “Registered Foreign Manufacturer” in the same way that a Japanese manufacturer is registered. Typically, an MAH can make a registration application on behalf of a U.S. manufacturer. A U.S. manufacturer that lacks a Japanese subsidiary can receive and maintain the marketing approval under its own name. However, the U.S. firm will need to designate an MAH when applying for product approval. This Designated MAH (D-MAH) will have to assume the same responsibilities as an MAH. A D-MAH can be a regulatory consulting company or an importer/distributor that holds an MAH license. When a regulatory consultant is designated as an MAH, a U.S. company will need to have a Japanese distribution partner since a regulatory consulting company will not act as a distributor. If a U.S. firm has a subsidiary in Japan, that subsidiary can become an MAH and then obtain the marketing approval for each product. If a U.S. firm does not have a subsidiary in Japan, the company has three options to consider in order to conduct business in Japan:

1. The U.S. firm can ask their importer/distributor to obtain the marketing approval under the name of the importer/distributor. In this case, the importer/distributor will have complete control of the U.S. firm’s products when the products are marketed in Japan.

2. The U.S. firm can obtain the marketing approval under their own name by designating their importer/distributor as a D-MAH.

3. The U.S. firm can obtain the marketing approval under their own name via a neutral third party such as regulatory consulting firms that have a “license for manufacturing/marketing business” by designating them as a D-MAH.

Current Market Trends

The Japanese market for medical devices is large and established at $22.7 billion in 2015. Japan's medical device market exhibited a compound annual growth rate (CAGR) of 3.5% in Yen terms from 2010 to 2015, and all individual product categories other than diagnostic x-ray equipment and related supplies exhibited positive growth. The market remains heavily dependent on imports, especially sophisticated medical devices such as pacemakers, PTCA catheters and orthopedic implants. In 2015, U.S. products represented an approximately 44 percent import share and accounted for 23 percent of Japan's total device market (valued at approximately US$6.5 billion). Please note that these figures do not include in-vitro diagnostic (IVD) products as they are classified as pharmaceuticals in Japan. A number of U.S. companies have substantial production capacity in Japan. As such, the total market share of U.S.-origin medical devices in Japan would be significantly higher than suggested by official statistics. According to the American Medical Devices and Diagnostics Manufacturers’ Association (AMDD), a trade association of Japanese operations of U.S. medical devices and diagnostics companies, the total sales of its member companies reached Yen 1.8 trillion ($ 14.9 billion) in 2015, which represented 67% of the Japanese medical device market (including IVDs) in terms of sales.

Main Competitors

The major product categories comprising Japan’s domestic medical device production include: diagnostic imaging equipment; therapeutic and surgical equipment; biophenomena measuring and monitoring systems, home therapeutic equipment, dialyzers, and endoscopes. Japanese medical device companies maintain high market share in those product segments. Top Japanese medical device companies, in terms of sales, include Terumo, NIPRO, Olympus Medical Systems, Hitachi Medico, Nihon Koden, and Fukuda Denshi. U.S. medical device companies produce a wide variety of medical devices, but they are especially strong in sophisticated segments of the medical market such as pacemakers, advanced interventional cardiology products, orthopedic implants, laser surgical equipment, and advanced diagnostic imaging equipment. Most major U.S. and foreign medical device firms have either a Japan office or a Japanese partner. As such, new-to-market U.S. companies will face strong competition not only from Japanese companies but also from American and multinational firms already in the market.

Current Demand

Given Japan's aging population and the increasing number of patients with chronic and life-style diseases, medical devices that alleviate pain, complement lost functions, and improve the quality of life should show steady growth in demand. Also, the markets for in-home care devices, technologies, and health IT related products are expected to grow as the number of people in out-patient care increases. Due to stronger consumer health concerns, other promising growth areas include self-care and preventive care medical devices and products.

Registration Process

Japan’s medical device classification system is based on the Japanese Medical Device Nomenclature (JMDN) codes which are different from U.S. and European classifications. Review processes for medical devices differ depending on the classification. Medical devices are classified by risk level into four classes (Class 1, Class 2, Class 3 and Class 4). Class 1 (lowest risk) is defined as general medical devices; Class 2 (relatively low risk) is defined as controlled medical devices; Class 3 (relatively high risk) and Class 4 (highest risk) are defined as specifically controlled devices. General medical devices can be marketed by submitting a notification to the Pharmaceutical and Medical Device Agency (PMDA). Controlled medical devices, with established certification standards, can be reviewed by third-party certification bodies. Controlled medical devices without certification standards and specifically controlled devices must be reviewed by PMDA and approved by MHLW.

Reimbursement

In order to effectively market most medical devices in Japan, those products must be listed in the Japan's reimbursement system. The reimbursement rate, or price, granted to a given medical device by the Ministry of Health, Labor and Welfare is effective under all insurance schemes, whether public, private or employer based. There are five product reimbursement classifications:

  • A1 (products that are included in the technical fee paid to the doctor for a given procedure, ie there is no separate reimbursement for the device);
  • A2 and B (products that are reimbursed under an existing "by-function" category, ie the price assigned is the same as for similar items already on the market);
  • C1 (products requiring creation of a new by-function category);
  • C2 (completely new products or technology).

Category A1 products become eligible for reimbursement 20 days following a company's request for listing. Category A2 and B products become eligible for reimbursement on the first day of the month if the request for reimbursement is made in the first 10 days of the previous month. Category C1 and C2 products become eligible for reimbursement four times a year (March, June, September and December). Please see http://www.mhlw.go.jp/file/04-Houdouhappyou-11123000-Iyakushokuhinkyoku-Shinsakanrika/0000135598.pdf for further details regarding the medical device reimbursement system in Japan.

Barriers

While the market for U.S. medical equipment in Japan remains strong, U.S. firms face challenges with pricing and reimbursement due to the GOJ‘s efforts to contain overall healthcare costs as a result of Japan’s aging population. In June 2016, Japan decided to postpone, for the second time, the scheduled consumption tax hike in April 2017 (from 8% to 10%) to October 2019. When the tax hike was planned in April 2017, the Ministry of Finance was demanding that reimbursement prices be trimmed based on market prices by carrying out an irregular price revision, which would have led to de facto annual revisions (the scheduled biennial price revisions occur in even-numbered fiscal years). The decision helped the industry avert three consecutive years of price revisions in 2016-2018; however, it has created a more challenging financial environment as it generated additional revenues to fund healthcare expenditure, especially when Japan is aiming to achieve a primary surplus by JFY2020.

Procurement & Tenders

In order to participate in the Government procurements, the seller must usually be qualified based on their history of operations, financial status, etc. For further information about the GOJ’s procurement, please see the Ministry of Foreign Affair’s website at http://www.mofa.go.jp/policy/economy/procurement/index.html. Also, the Japan External Trade Organization (JETRO) provides the Japanese Government Procurement Database System on their website at https://www.jetro.go.jp/en/database/procurement/.

Trade Events

 

Medical Japan

Osaka

February 21-23, 2018

http://medical-jpn.jp/en/

 

Bio Asia International Conference

Tokyo

March13, 2018

http://10times.com/bio-asia-international

 

International Technical Exhibition of Medical Imaging

Yokohama

April13-15,2018

http://www.jira-net.or.jp/e/index.htm

 

CPhI Japan

Tokyo

April18-20, 2018

http://www.cphi.com/japan/home/

 

MEDTEC Japan

Tokyo

April 18-20, 2018

http://medtecjapan.com/en

 

BIOtech Japan

Tokyo

June 27-29, 201

http://www.bio-t.jp/en/About/Outline/

 

INTERPHEX Japan

Tokyo

June 27-29, 2018

http://www.interphex.jp/en/Home/

 

International Modern Hospital Show (IMHS)

Tokyo

July 12-14, 2017

http://noma-hs.jp/hs/2017/en/outline/index.html

 

BioJapan

Yokohama

October 11-13, 2017

http://www.jba.or.jp/pc/en/bio/

 

CEATEC Japan

Chiba

October 3-6, 2017

http://www.ceatec.com/en/application/

 

HOSPEX Japan (International Hospital Engineering Exhibition)

Tokyo

November 20-22, 2017

http://www.jma.or.jp/hospex/en/index.html

Local Associations

The American Medical Devices and Diagnostics Manufacturers Association (AMDD): https://amdd.jp/en/index.html

Japan Federation of Medical Device Associations (JFMDA): www.jfmda.gr.jp

Government Links:

Ministry of Health, Labour and Welfare (MHLW): www.mhlw.go.jp

Pharmaceutical and Medical Device Agency (PMDA): www.pmda.go.jp

FAQs

Can we file a product approval application to PMDA in a language other than Japanese?

No, PMDA requires all forms related to the product approval application to be submitted in Japanese.

Can we submit foreign clinical data for a product approval in Japan?

Yes, PMDA often accepts foreign clinical data of medical devices for a product approval. For further information, please see the following notifications:

https://www.pmda.go.jp/files/000153213.pdf

https://www.pmda.go.jp/files/000153073.pdf

Can we own a product approval status under our own name?

Yes, a U.S. manufacturer that lacks a Japanese subsidiary can receive and maintain the marketing approval under its own name. However, the U.S. firm will need to designate an in-country licensed Marketing Authorization Holder (MAH) when applying for product approval.

U.S. Commercial Service Contact Information

Name: Hiroyuki Hanawa

Position: Senior Commercial Specialist

Email: Hiroyuki.Hanawa@trade.gov

Phone: +81-3-3224-5083

Available Market Research/Best Prospects

  Country Commercial Guide

Best prospects (2-5)

  • Sophisticated new medical technologies and therapies, including minimally invasive medical devices
  • Regenerative medicine
  • Health IT

Market Size

Healthcare spending

Yen 40,619 billion (2013)

... as percent of GDP

10.2% (2014)

... of which spent on inpatient services (including long-term care)

37.4% (2013)

... of which spent on pharmaceuticals/consumables

22.5% (2013)

... of which spent on outpatient services

34.4% (2013)

Hospitals, Procedures, Healthcare Professionals

Number of hospitals

8,480 (2015)

…Public

1,556

…Private and others

6,925

Number of hospital beds

1,673,669 (2015)

... available beds per capita

1,232.1 beds/100,000 people

...of which in general hospitals

1,565,968

...of which in general clinics

107,626

Physicians

311,205 (2014)

...of which surgeons

28,043 (2014)

...of which internists

61,317 (2014)

...of which pediatricians

16,758 (2014)

Dentists

103,972 (2014)

Demographics

Population

126,702,133 (July 2016)

Life expectancy men/women

Male: 81.7 years

Female: 88.5 years (2016)

Infant mortality

2 deaths/1,000 live births (2016)

Percent of population older than 65

26.0% (2012)

...projection, 2030

31.6% (2012)

Annual deaths

9.6 deaths/1,000 population (2016)

...caused by [highest disease burden]

Malignant neoplasms

...caused by [second highest]

Heart diseases

Prevalence of [fastest growing disease burden]

Malignant neoplasms


  Notice to Visitors!


  The link you have chosen will take you to a non-U.S. Government website.

  If the page does not appear in 5 seconds, please click this: outside web site

  Export.gov is managed by the International Trade Administration and external links are covered by its website  disclaimer statement.


  Notice to Visitors!


  The link you have chosen will take you to a non-U.S. Government website.

  If the page does not appear in 5 seconds, please click this: outside web site

  BuyUSA.gov is managed by the International Trade Administration and external links are covered by its website disclaimer statement.